MedTrace Logo

Melanocortin Gene Expression in Lymphocytes of Polymyalgia Patients

NCT05681676 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 9

Last updated 2023-01-12

No results posted yet for this study

Summary

Polymyalgia rheumatica (PMR) is a systemic inflammatory disorder with unknown etiology and overlapping symptoms with giant cell arthritis and rheumatoid arthritis (RA). The proteomic profile of PMR patients remains uncharacterized and biomarker studies very limited. The primary aim of this study was to thoroughly investigate the lymphocyte expression of melanocortin receptors, and the serum proteome during glucocorticoid treatment of PMR with a focus on acute-phase reactions, the complement system, and pro-inflammatory cytokines.

Conditions

  • Polymyalgia Rheumatica

Interventions

OTHER

Blood samples before and after standard of care of polymyalgia rheumatica

Blood samples were taken before glucocorticoid treatment and three months after.

Sponsors & Collaborators

  • Aalborg University

    lead OTHER

Eligibility

Min Age
50 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2012-03-01
Primary Completion
2015-12-01
Completion
2022-12-01

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05681676 on ClinicalTrials.gov